Is Immunovant Inc. (NASDAQ: IMVT) Still A Buy After sinking -7.55% Last Week? – Marketing Sentinel
Home  »  Company   »  Is Immunovant Inc. (NASDAQ: IMVT) Still A Buy Afte...

Is Immunovant Inc. (NASDAQ: IMVT) Still A Buy After sinking -7.55% Last Week?

During the last session, Immunovant Inc. (NASDAQ:IMVT)’s traded shares were 0.41 million. At the end of the trading day, the stock’s price was $4.04, reflecting an intraday gain of 3.06% or $0.12. The 52-week high for the IMVT share is $16.05, that puts it down -297.28 from that peak though still a striking 8.17% gain since the share price plummeted to a 52-week low of $3.71. The company’s market capitalization is $488.52M, and the average trade volume was 543.32K shares over the past three months.

Immunovant Inc. (NASDAQ:IMVT) trade information

Immunovant Inc. (IMVT) registered a 3.06% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.06% in intraday trading to $4.04 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -7.55%, and it has moved by -21.09% in 30 days. Based on these gigs, the overall price performance for the year is -73.94%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Immunovant Inc. (IMVT) estimates and forecasts

Statistics show that Immunovant Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Immunovant Inc. (IMVT) shares have gone down -52.30% during the last six months, with a year-to-date growth rate less than the industry average at -16.39% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -6.30% this quarter and then drop -20.70% in the quarter after that.

While earnings are projected to return 20.30% in 2022.

IMVT Dividends

Immunovant Inc. is due to release its next quarterly earnings between February 14 and February 18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Immunovant Inc. (NASDAQ:IMVT)’s Major holders

Immunovant Inc. insiders own 64.70% of total outstanding shares while institutional holders control 34.79%, with the float percentage being 98.56%. Eventide Asset Management LLC is the largest shareholder of the company, while 188 institutions own stock in it. As of Dec 30, 2021, the company held over 4.95 million shares (or 4.25% of all shares), a total value of $42.17 million in shares.

The next largest institutional holding, with 4.78 million shares, is of Deep Track Capital, LP’s that is approximately 4.10% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $40.68 million.

Also, the Mutual Funds coming in first place with the largest holdings of Immunovant Inc. (IMVT) shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Dec 30, 2021 indicates that Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund owns about 4.95 million shares. This amounts to just over 4.25 percent of the company’s overall shares, with a $42.17 million market value. The same data shows that the other fund manager holds slightly less at 1.98 million, or about 1.70% of the stock, which is worth about $16.87 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts